Costas Demetzos
Overview
Explore the profile of Costas Demetzos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
891
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kosti E, Sotiropoulou H, Tsichlis I, Tsakiri M, Naziris N, Demetzos C
Materials (Basel)
. 2024 Nov;
17(22).
PMID: 39597287
The aim of the present study is to evaluate the stability of DMPC:Pluronic F-127 and DPPC:Pluronic F-127 liposomes, both with and without incorporated quercetin. Quercetin belongs to the class of...
2.
Demetzos C
AAPS J
. 2024 Jul;
26(4):74.
PMID: 38955936
The paper highlights the necessity for a robust regulatory framework for assessing nanomedicines and their off-patent counterparts, termed as nanosimilar, which could be considered as 'similar' to the prototype nanomedicine,based...
3.
Tsakiri M, Tsichlis I, Zivko C, Demetzos C, Mahairaki V
Pharmaceutics
. 2024 Mar;
16(3).
PMID: 38543244
Neurodegenerative diseases, such as Alzheimer's and Parkinson's, affect a wide variety of the population and pose significant challenges with progressive and irreversible neural cell loss. The limitations of brain-targeting therapies...
4.
Tsakiri M, Tabriz A, Naziris N, Rahali K, Douroumis D, Demetzos C
Int J Pharm
. 2024 Jan;
651:123788.
PMID: 38185341
Exosomes are naturally derived information carriers that present interest as drug delivery systems. However, their vague cargo and isolation difficulties hinder their use in clinical practice. To overcome these limitations,...
5.
Stangel C, Kagkoura A, Pippa N, Stellas D, Zhang M, Okazaki T, et al.
Nanoscale Adv
. 2023 Dec;
5(24):6847-6857.
PMID: 38059018
The current study emphasizes the minimal toxicity observed and for carbon nanohorns (CNHs) modified with third generation polyamidoamine (PAMAM) dendrimers. Initially, we investigated the interactions between CNH-PAMAM and lipid bilayers,...
6.
Tsichlis I, Manou A, Manolopoulou V, Matskou K, Chountoulesi M, Pletsa V, et al.
Materials (Basel)
. 2023 Aug;
16(16).
PMID: 37629800
The aim of the present study is the development, physicochemical characterization, and in vitro cytotoxicity evaluation of both empty and quercetin-loaded HSPC (hydrogenated soy phosphatidylcholine) liposomes, GMO (glyceryl monooleate) liquid...
7.
Naziris N, Demetzos C
Adv Exp Med Biol
. 2023 Aug;
1425:575-589.
PMID: 37581831
Herein we present the modern issue of new health technologies that emerge in Medicine and Therapeutics, with regard to their development, regulatory framework, approval, and post-approval monitoring. The European law...
8.
Sekowski S, Naziris N, Chountoulesi M, Olchowik-Grabarek E, Czerkas K, Veiko A, et al.
J Funct Biomater
. 2023 Jun;
14(6).
PMID: 37367260
Tannins are natural plant origin polyphenols that are promising compounds for pharmacological applications due to their strong and different biological activities, including antibacterial activity. Our previous studies demonstrated that sumac...
9.
Maswadeh H, Khan A, Alorainy M, Al-Wabel N, Demetzos C
Am J Cancer Res
. 2023 Mar;
13(2):379-393.
PMID: 36895979
The temperature sensitive liposomal formulations are a promising tool to improve the therapeutic index of the drugs with minimal toxicity. The aim of this study was to investigate the potential...
10.
Xekouki K, Lagopati N, Demetzos C, Gazouli M, Pippa N
J Liposome Res
. 2023 Mar;
33(3):214-233.
PMID: 36856671
Nanovaccines have shown to be effective, and this is the reason they are preferred than conventional vaccines. The scope of this review is to describe the role, mechanisms, and advantages...